BioLife Solutions Inc (BLFS)vsWest Pharmaceutical Services Inc (WST)
BLFS
BioLife Solutions Inc
$38.61
0.00%
HEALTHCARE · Cap: $1.89B
WST
West Pharmaceutical Services Inc
$383.91
-0.03%
HEALTHCARE · Cap: $26.96B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 3018% more annual revenue ($3.33B vs $106.69M). BLFS leads profitability with a 54.3% profit margin vs 17.0%. WST appears more attractively valued with a PEG of 3.43. WST earns a higher WallStSmart Score of 56/100 (C).
BLFS
Hold46
out of 100
Grade: D+
WST
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.6%
Fair Value
$21.68
Current Price
$38.61
$16.93 premium
Margin of Safety
-44.6%
Fair Value
$170.28
Current Price
$383.91
$213.63 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 54 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 21.5% year-over-year
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Trading at 9.0x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Profit Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 54.3% and operating margin at 6.0%. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : BLFS
The primary concerns for BLFS are P/E Ratio, Market Cap, PEG Ratio.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 49.2x leaves little room for execution misses.
Key Dynamics to Monitor
BLFS profiles as a growth stock while WST is a mature play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.82 — expect wider price swings.
BLFS is growing revenue faster at 21.5% — sustainability is the question.
WST generates stronger free cash flow (81M), providing more financial flexibility.
Bottom Line
WST scores higher overall (56/100 vs 46/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?